0000899243-20-018893.txt : 20200709 0000899243-20-018893.hdr.sgml : 20200709 20200709214637 ACCESSION NUMBER: 0000899243-20-018893 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200707 FILED AS OF DATE: 20200709 DATE AS OF CHANGE: 20200709 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zaks Tal Zvi CENTRAL INDEX KEY: 0001690927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 201021624 MAIL ADDRESS: STREET 1: 122 BELLEVUE STREET CITY: NEWTON STATE: MA ZIP: 02458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-07 0 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer Common Stock 2020-07-07 4 M 0 22936 12.21 A 22936 D Common Stock 2020-07-07 4 M 0 24121 19.15 A 47057 D Common Stock 2020-07-07 4 M 0 15631 19.15 A 62688 D Common Stock 2020-07-07 4 S 0 23787 58.21 D 38901 D Common Stock 2020-07-07 4 S 0 17393 58.97 D 21508 D Common Stock 2020-07-07 4 S 0 7739 60.05 D 13769 D Common Stock 2020-07-07 4 S 0 13769 60.98 D 0 D Common Stock 2020-07-08 4 M 0 10000 20.93 A 10000 D Common Stock 2020-07-08 4 M 0 10000 19.15 A 20000 D Common Stock 2020-07-08 4 S 0 3238 60.27 D 16762 D Common Stock 2020-07-08 4 S 0 15619 61.35 D 1143 D Common Stock 2020-07-08 4 S 0 1143 62.16 D 0 D Stock Option (Right to Buy) 12.21 2020-07-07 4 M 0 22936 0.00 D 2027-10-03 Common Stock 22936 240824 D Stock Option (Right to Buy) 19.15 2020-07-07 4 M 0 24121 0.00 D 2026-08-10 Common Stock 24121 260421 D Stock Option (Right to Buy) 19.15 2020-07-07 4 M 0 15631 0.00 D 2026-08-10 Common Stock 15631 244790 D Stock Option (Right to Buy) 20.93 2020-07-08 4 M 0 10000 0.00 D 2020-03-08 2029-03-08 Common Stock 10000 329195 D Stock Option (Right to Buy) 19.15 2020-07-08 4 M 0 10000 0.00 D 2026-08-10 Common Stock 10000 234790 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.57 to $58.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.58 to $59.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.61 to $60.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.63 to $61.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. This option is fully vested and exercisable. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.77 to $60.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.80 to $61.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.94 to $62.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). /s/ Lori Henderson, as Attorney-in-Fact 2020-07-09